Skip to main content

Advertisement

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Article metrics

The original article was published in Alzheimer's Research & Therapy 2017 9:95

Correction

Following publication of the original article [1], the authors reported errors in the formatting of the table. The details of the errors are as follows:

In Table 1, the data presented do not correspond to the row title:

  • The education row currently contains incorrect data.

  • The weight row currently contains the years of education.

  • The APOEε4 genotype row currently contains the weight data.

In Table 1, the data should be displayed as follows:

Variable

Intention-to-treat population (n = 797)

Placebo

(n = 266)

Gantenerumab

105 mg

(n = 271)

Gantenerumab

225 mg

(n = 260)

Age, years, mean (SD)

69.5 (7.5)

70.3 (7.0)

71.3 (7.1)

Education, years, mean (SD)

12.6 (4.3)

12.9 (4.8)

12.1 (4.5)

Weight, kg, mean (SD)

69.8 (12.9)

70.5 (13.6)

70.1 (12.5)

APOEε4 genotype, %a

Reference

  1. 1.

    Ostrowitzki S, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimer's Research & Therapy. 2017;9:95. https://doi.org/10.1186/s13195-017-0318-y.

Download references

Author information

Correspondence to Paulo Fontoura.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ostrowitzki, S., Lasser, R.A., Dorflinger, E. et al. Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alz Res Therapy 10, 99 (2018) doi:10.1186/s13195-018-0409-4

Download citation